Has TB-500 Been Tested in Human Clinical Trials? What Actually Exists

Q: So has TB-500 ever been in a clinical trial?

The synthetic fragment sold as TB-500 has not. A related but different compound, full-length thymosin beta-4 formulated as RGN-259 eye drops by RegeneRx Biopharmaceuticals, has been through human clinical trials for dry eye disease and neurotrophic keratopathy. That is a different molecule, delivery route, and indication from the injectable research chemical.

Q: Did the RGN-259 trials show it works?

Results have been mixed across the program's trials, with some showing improvement on certain endpoints and others not clearly separating from placebo on their primary endpoints. High placebo response is common in dry eye trials generally, which complicates interpretation. It is not accurate to describe the program as having definitively proven clinical efficacy.

> Research disclaimer: This article summarizes published and publicly disclosed human trial history for thymosin beta-4-derived compounds, for informational purposes only. TB-500, as sold under that name, is a research chemical, is not FDA-approved, and has not itself been tested in the trials described below. Nothing here is medical advice.

Has TB-500 Actually Been Tested in Humans?

Short answer: Not directly, no. A thymosin beta-4-derived compound has been tested in humans — but it's a different formulation from the synthetic fragment sold under the name "TB-500," and that distinction matters more than most summaries of this topic acknowledge. The compound that reached human clinical trials is RGN-259, an ophthalmic drop developed by RegeneRx Biopharmaceuticals using full-length thymosin beta-4, studied for corneal and ocular surface healing. The vast majority of what gets cited as "TB-500 research" — tendon repair, cardiac protection, wound healing mechanisms — is animal or cell-culture work, not human trial data.

If you've read elsewhere on this site that TB-500 is the synthetic 7-amino-acid fragment of thymosin beta-4 (Ac-LKKTETQ), while RGN-259 uses the full 43-amino-acid protein, that's the crux of why "there have been human trials on thymosin beta-4" and "TB-500 has been tested in humans" are not the same claim. For a sense of what a compound with actual completed Phase III trials and FDA approval looks like by comparison, see our TB-500 vs Tesamorelin comparison — a genuinely different tier of evidence than anything in TB-500's own trial history.

This near-total absence of human trial data is also what separates TB-500 from a clinical alternative like autologous stem cell therapy, which — whatever its own evidence and regulatory limitations — does have a meaningful volume of published human trials behind it; see our TB-500 vs stem cell therapy comparison for how those two evidence bases actually stack up.

The RGN-259 trials are also worth contrasting with a much larger human trial base that gets attributed to TB-500 incorrectly: Thymosin Alpha-1's COVID-19 research, which covers over 11,000 subjects across more than 30 trials — an entirely different peptide with an entirely different mechanism. Our TB-500 and long COVID guide breaks down that specific mix-up.

---

What RGN-259 Actually Is, and Isn't

RegeneRx Biopharmaceuticals has developed thymosin beta-4-based formulations for topical and ophthalmic use since the early 2000s, building on the same actin-regulation and cell-migration research discussed throughout this site's mechanism articles. RGN-259 is their ophthalmic formulation, delivered as eye drops rather than injected, and studied primarily for two indications: dry eye disease and neurotrophic keratopathy (a condition involving impaired corneal healing due to reduced nerve sensation).

A few points worth separating clearly:

The molecule is full-length Tβ4, not the synthetic fragment marketed as TB-500. Full-length Tβ4 retains functions beyond the LKKTET actin-binding motif that the fragment carries, so results with one don't automatically apply to the other.

The delivery route is topical/ophthalmic, not subcutaneous injection — the route most TB-500 research chemical use discusses. Bioavailability, tissue exposure, and systemic effects differ substantially between an eye drop and an injected compound.

The trials were run by a pharmaceutical company under an Investigational New Drug program, meaning this is regulated clinical development toward a potential approved drug — a different regulatory context from a research chemical sold without clinical oversight.

RegeneRx has also explored other thymosin beta-4 formulations for skin and connective tissue applications over the years, generally as topical preparations rather than systemic injections. None of these programs are the same product as the injectable TB-500 fragment discussed elsewhere on this site.

A separate, less-discussed program is worth naming here too: RGN-352, an intravenous formulation of full-length Tβ4 that RegeneRx studied for cardiac indications, with published Phase 1 dosing in the tens to low-thousands of milligrams range. It's a different molecule, route, and indication from RGN-259 as well — see our animal study doses vs. human equivalent guide for those specific figures and how they compare to both animal research and community research-chemical dosing.

RegeneRx also ran a third, frequently overlooked human trial program: RGN-137, a topical gel tested in Phase II trials for pressure ulcers and venous stasis ulcers. See our dedicated breakdown of those chronic-wound trial results for what the dosing, safety, and efficacy data actually showed.

---

What the Human Trial Results Actually Show

This is the part where caution matters most, because trial outcomes for ophthalmic Tβ4 have not been uniformly positive. Published and publicly disclosed results across RGN-259's development program have been mixed — some trials reported improvement on certain corneal healing or symptom measures, while others did not clearly separate from placebo on their pre-specified primary endpoints. That mixed picture is normal for ophthalmic drug development generally, where placebo response rates in dry eye trials tend to run high, but it means the honest summary is "inconsistent evidence of benefit in a narrow indication," not "proven effective in humans."

It's also worth being direct about scope: even in the best-case reading of that trial history, the studied indication is ocular surface healing — dry eye and corneal epithelial repair. None of it speaks to tendon injury, muscle recovery, cardiac tissue, or the other injury contexts covered elsewhere on this site. Extrapolating ophthalmic trial data to systemic injectable use is not something the trials themselves support.

---

Why "TB-500 Has Been Studied in Human Trials" Is a Misleading Shortcut

The shortcut happens because both compounds share a name (thymosin beta-4) and a discovery lineage, and because RGN-259's trial existence gets cited as evidence that "the peptide" has clinical backing. Three things get collapsed into one claim that shouldn't be:

1. Different molecule — fragment vs. full-length protein.
2. Different route — injection vs. topical eye drop.
3. Different indication — general tissue/tendon/muscle repair vs. ocular surface healing specifically.

None of that means the underlying actin-regulation mechanism is fictional — it's well-documented in cell and animal models, as covered in the mechanism-of-action research on this site. It means the specific claim "TB-500 has clinical trial data behind it" overstates what actually exists for the product sold under that name.

---

A Note on Verifying What You're Actually Working With

Given how much confusion exists between "thymosin beta-4 has been in clinical trials" and "this specific vial of TB-500 has clinical backing," sourcing verification becomes more important, not less. A certificate of analysis at minimum confirms you're working with the fragment your research protocol is designed around. Apollo Peptide Sciences publishes third-party HPLC testing and certificates of analysis for its TB-500, which is the baseline documentation for knowing what compound a given research finding might or might not apply to.

---

What's Genuinely Unknown

No human trials exist for injectable TB-500 (the synthetic fragment) in any indication — tendon, muscle, cardiac, kidney, or otherwise. The kidney research area in particular has no human data at all, not even the limited Phase I/II history that exists for cardiac applications.

Systemic pharmacokinetics of the fragment in humans haven't been published; PK data that does exist is largely animal-derived, as discussed in this site's half-life research.

Whether full-length Tβ4's ophthalmic trial results have any relevance to the fragment's injectable use hasn't been directly studied — the two are different molecules by design.

Long-term human safety data for the fragment doesn't exist in published form, regulated trial or otherwise.

---

Frequently Asked Questions

So has TB-500 ever been in a clinical trial?

The synthetic fragment sold as TB-500 — no. A related but different compound, full-length thymosin beta-4 formulated as RGN-259 eye drops by RegeneRx Biopharmaceuticals, has been through human clinical trials for dry eye disease and neurotrophic keratopathy. That's a different molecule, delivery route, and indication from the injectable research chemical.

Did the RGN-259 trials show it works?

Results have been mixed across the program's trials — some showed improvement on certain endpoints, others did not clearly separate from placebo on their primary endpoints. High placebo response is common in dry eye trials generally, which complicates interpretation. It is not accurate to describe the program as having definitively proven clinical efficacy.

Why do people say TB-500 has "clinical research" behind it?

Usually because RGN-259's trial history gets cited without the distinction being made clear — that it's full-length Tβ4, delivered topically to the eye, for an ocular indication, rather than the injectable fragment used in most TB-500 research-chemical protocols.

Are there any trials planned or underway for the injectable fragment?

None that are publicly disclosed. RegeneRx's public development pipeline has focused on topical and ophthalmic formulations of full-length Tβ4, not the isolated fragment sold under the TB-500 name.

Does the animal research on TB-500 mean it's close to human trials?

Not necessarily. A substantial body of animal and cell-culture research exists on the fragment's mechanism, as covered throughout this site, but preclinical mechanistic research and a formal clinical development program are very different stages, and there's no public indication the fragment itself is in a regulated pipeline.

Sourcing Quality Research Peptides

Given how easily "thymosin beta-4 in clinical trials" gets conflated with "TB-500 the injectable fragment," knowing exactly what compound is in a given vial matters. Apollo Peptide Sciences provides independent third-party testing and certificates of analysis on its TB-500, confirming the fragment identity before any research conclusions get drawn from it.

---